VVM
GLUE icon

Versant Venture Management’s Monte Rosa Therapeutics GLUE Stock Holding History

Versant Venture Management’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$52.3M Sell
3,180,780
-1,201,907
-27% -$23M 37% 1
2025
Q4 		$68.7M Sell
4,382,687
-1,270,235
-22% -$17.1M 45.49% 1
2025
Q3 		$41.9M Hold
5,652,922
– – 19.72% 2
2025
Q2 		$25.5M Hold
5,652,922
– – 31.04% 1
2025
Q1 		$26.2M Hold
5,652,922
– – 43.56% 1
2024
Q4 		$39.2M Buy
+5,652,922
New +$42.4M 45.22% 1

Other funds holding GLUE

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Versant Venture Management's GLUE Position: Q1 2026 in Review

Versant Venture Management reduced its Monte Rosa Therapeutics (GLUE) stake by 27% in Q1 2026, selling an estimated $23M and leaving 3,180,780 shares worth $52.3M. The position accounts for 37% of the portfolio, ranked #1.

Versant Venture Management first reported a position in GLUE in Q4 2024 and has held it in 6 quarters since. The position peaked at $68.7M in Q4 2025. 190 funds tracked by Wall St. Rank hold GLUE as of Q1 2026.

  • Versant Venture Management held 3,180,780 shares of Monte Rosa Therapeutics worth $52.3M as of Q1 2026.
  • Versant Venture Management sold 1,201,907 Monte Rosa Therapeutics shares in Q1 2026, an estimated $23M.
  • Monte Rosa Therapeutics made up 37% of Versant Venture Management's portfolio in Q1 2026, its #1 holding.
  • Versant Venture Management first reported a position in Monte Rosa Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • Versant Venture Management's Monte Rosa Therapeutics position peaked at $68.7M in Q4 2025.
  • 190 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q1 2026.

Based on Versant Venture Management's 13F filing for Q1 2026, filed 5 May 2026.